SOURCE: Arrayit Corporation

Arrayit Corporation

October 28, 2009 07:00 ET

Arrayit Announces NanoPrint Sale to Leukemia Center in Poland

Purchase of Arrayit Microarray System Will Play Integral Role in Targeted Cancer Testing

SUNNYVALE, CA--(Marketwire - October 28, 2009) - Arrayit Corporation (OTCBB: ARYC) today announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies (CENAT) in Poznan, Poland. The Arrayit NanoPrint Microarrayer will be used by CENAT for scientific and medical collaborations throughout the prosperous democracy.

"We are very excited to have CENAT as a customer for our NanoPrint enterprise level microarray robot," stated Rene Schena, CEO and Chairman of Arrayit. "This relationship demonstrates the commercial value of our core technology for cancer research and diagnostics."

"The Arrayit microarray manufacturing platform will help accelerate on-going myeloid leukemia cancer analysis at CENAT," stated Dr. Luiza Handschuh, CENAT Laboratory Director. "Arrayit's system offers us the ability to make high quality microarrays of all types that will greatly enhance cancer research by enabling quantitative DNA, RNA and protein analysis."

Versatile NanoPrint microarrayers have also been installed at other major research and diagnostics centers including Harvard University in Massachusetts, Sandia National Laboratories in New Mexico, Scripps Research Institute in Florida, The Biodesign Institute in Arizona, and Mount Sinai School of Medicine in New York City.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.

Contact Information